Signs of AML may be present years before diagnosis
December 13, 2017
Patients with acute myeloid leukemia (AML) may have genetic mutations in their blood indicating they are at high risk of developing the disease about nine years before diagnosis, according to research from Weill Cornell Medicine and NewYork-Presbyterian investigators. They presented their findings at the 59th annual American Society of Hematology meeting Dec. 10 in Atlanta.
Tumor Models
November 10, 2017
The Englander Institute for Precision Medicine (EIPM) has developed unique models to study cancer in its laboratories, such as growing mini tumors called ‘organoids’.
Human cancer tissue that is grown into organoids in the laboratory could be used to test drug responses and to personalize therapy.
Organoids can be made to resemble organs or tissues such as gut, kidney, pancreas, liver, breast, prostate, and even brain tissue, all complete with accurate micro-anatomy.
Targeting Cancer
November 10, 2017
Precision medicine harnesses a unique mix of personal genetic, genomic and clinical information to inform patients’ medical care, for both treatment and prevention of diseases. This information includes individual genomic DNA sequences, which can potentially identify variants that cause disease, and in some cases predict how a patient will respond to a particular drug.
New Big Data Approach Predicts Drug Toxicity in Humans
November 10, 2017
Researchers can now predict the odds of experimental drugs succeeding in clinical trials, thanks to a new data-driven approach developed by Weill Cornell Medicine scientists. The method detects toxic side effects that may disqualify drugs from human use, giving drug developers an early warning before initiating clinical trials, according to a new study published Sept. 15 in Cell Chemical Biology.
Precision Medicine Is More Than Genomic Sequencing
October 24, 2017
This is an excerpt of a story written by Robert H. Carlson, MBA, appearing on Medscape. Read the original article here.
Basing decisions about cancer treatment on mutations and other somatic genomic abnormalities has become a standard of care for patients with some tumors types, but the use of targeted therapies rarely leads to cure, and responses can be incomplete. If clinical decisions are to improve, both mutation data and cell context—the cellular and genomic milieu in which the mutations are found—must be considered.
Chemotherapy Drives Treatment Resistance in Bladder Cancer
October 17, 2017
Chemotherapy is indicated as the first line of treatment for advanced bladder cancer. New research by Weill Cornell Medicine and University of Trento scientists shows that while chemotherapy kills the most common type of bladder cancer, urothelial cancer, chemotherapy also shapes the genetic evolution of remaining urothelial cancer cell clones to become drug-resistant.
EXaCT-1 Precision Medicine Cancer Test Validated for Clinical Usage
October 3, 2017
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research.
Dr. Olivier Elemento Appointed EIPM Director
September 15, 2017
Dr. Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine. Dr. Elemento will also lead joint precision medicine efforts at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center.
A parting shot at cancer
June 23, 2017
For those hoping to fire a parting shot at their cancer, the Englander Institute of Precision Medicine (EIPM) has a unique opportunity.
Patients enrolled in precision medicine clinical trials at Weill Cornell Medicine/NewYork-Presbyterian can also consent to have their cases studied after their death.
The lasting legacy is the ultimate way to advance our understanding of cancer biology and contribute to future cures, says neuropathologist David J Pisapia, M.D.
How Mixed Reality is Transforming Collaborative Cancer Research
June 15, 2017
By Tim Hinchliffe. Source: Sociable
The ability to visualize big data in 3D and use that data to collaborate across disciplines through Mixed Reality is transforming cancer research.
As opposed to Virtual Reality (VR), Augmented or Mixed Reality (AR, MR) works by mapping holograms over real, physical space through the help of a head set. With Mixed Reality, you can still see and interact with your immediate environment instead of being absorbed completely in a simulated world like with VR.